Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2015 Jul;12(7):387-400.
doi: 10.1038/nrgastro.2015.94. Epub 2015 Jun 9.

Inflammasome activation and function in liver disease

Affiliations
Review

Inflammasome activation and function in liver disease

Gyongyi Szabo et al. Nat Rev Gastroenterol Hepatol. 2015 Jul.

Abstract

Inflammation contributes to the pathogenesis of most acute and chronic liver diseases. Inflammasomes are multiprotein complexes that can sense danger signals from damaged cells and pathogens and assemble to mediate caspase-1 activation, which proteolytically activates the cytokines IL-1β and IL-18. In contrast to other inflammatory responses, inflammasome activation uniquely requires two signals to induce inflammation, therefore setting an increased threshold. IL-1β, generated upon caspase-1 activation, provides positive feed-forward stimulation for inflammatory cytokines, thereby amplifying inflammation. Inflammasome activation has been studied in different human and experimental liver diseases and has been identified as a major contributor to hepatocyte damage, immune cell activation and amplification of liver inflammation. In this Review, we discuss the different types of inflammasomes, their activation and biological functions in the context of liver injury and disease progression. Specifically, we focus on the triggers of inflammasome activation in alcoholic steatohepatitis and NASH, chronic HCV infection, ischaemia-reperfusion injury and paracetamol-induced liver injury. The application and translation of these discoveries into therapies promises novel approaches in the treatment of inflammation in liver disease.

PubMed Disclaimer

References

    1. Eur Cytokine Netw. 2000 Sep;11(3):483-6 - PubMed
    1. Nat Med. 2007 Nov;13(11):1324-32 - PubMed
    1. J Gen Virol. 2012 Feb;93(Pt 2):235-46 - PubMed
    1. Hepatology. 2010 Jan;51(1):307-28 - PubMed
    1. Diabetes Res Clin Pract. 2014 Aug;105(2):141-50 - PubMed

MeSH terms

LinkOut - more resources